Home/Pipeline/PNB-281

PNB-281

Solid Tumors

PreclinicalActive

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Active

Company

Peptinovo Biopharma

About Peptinovo Biopharma

Peptinovo Biopharma is a private, pre-revenue biotech developing a novel nanoparticle drug delivery platform called PALM™ to reformulate and improve existing chemotherapies. The company's initial pipeline targets a broad range of solid tumors, with its lead asset, PNB-281 (paclitaxel), in late preclinical testing and aiming for an IND filing and first-in-human trials by late 2024. Founded in 2018 by seasoned industry veterans, the company leverages deep expertise in drug development to advance a platform that could significantly enhance the therapeutic index of multiple oncology drugs.

View full company profile

Therapeutic Areas

Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed